US research funding rules explained: cancel-anytime grants, optional peer review, and political screening

What’s being proposed? In plain terms, a new set of US rules would let federal agencies cancel research grants at any time, treat scientific peer review as optional in more programs, and route proposals through political offices to screen for disfavored or “forbidden” topics. If enacted, this would mark a sharp break from long-standing norms that buffer science decisions from partisan control.

Does this affect me now? Not immediately. These are proposed rules, not final. They must go through public comment and could be revised or blocked by courts or Congress. But labs, universities, and startups that rely on federal R&D funding should understand the potential impact and prepare contingency plans.

Quick summary: What would actually change

• Termination at government discretion (“cancel anytime”): Agencies could end a grant even if the research team is performing as promised, based on agency preference or policy shifts.
• Peer review optional: For more programs, agencies could bypass or downplay external scientific peer review in favor of internal judgment or political oversight.
• Political screening of topics: Political appointees or their staff could be empowered to screen proposals and steer funding away from disfavored subject areas.

While the exact text and scope matter, these three ideas—taken together—would reduce the predictability and independence that researchers expect from US federal grants.

Key terms, quickly defined

• Office of Management and Budget (OMB): A White House office that sets cross-government rules for grants and financial assistance. Its Uniform Guidance (2 CFR 200) often dictates the terms and conditions agencies must use.
• Grant vs. contract vs. cooperative agreement:
  • Grants fund investigator-initiated work in the public interest with substantial researcher autonomy.
  • Contracts procure specific deliverables for government needs under stricter control.
  • Cooperative agreements sit in between, with substantial agency involvement.
• Peer review: Evaluation by independent subject-matter experts who score proposals on merit, feasibility, and impact. At NIH and NSF, external peer review plus programmatic review is the backbone of award decisions.
• Political appointees: Senior officials selected by the administration. Norms and, at some agencies, statutes have historically limited their direct role in individual scientific award decisions.

Why this matters

• Reliability is the currency of science funding. Labs make multi-year hires, purchase equipment, and commit to long experiments because federal grants are relatively stable. Cancel-at-will rules undermine that stability.
• Peer review protects quality and shields decisions from partisan swings. Making it optional raises the risk that scientific merit is sidelined.
• Content-based screening can chill entire fields. If researchers fear certain topics could be flagged, they self-censor, avoid emerging areas, or exit publicly funded research.
• Economic spillovers are at stake. University labs train the STEM workforce and seed startups. Funding whiplash and uncertainty can hamper regional innovation ecosystems.

What’s different from current practice

• Today, agencies can already terminate for cause (e.g., fraud, nonperformance) and, in some cases, by mutual consent. The new approach would emphasize termination at the agency’s convenience—even when the team complies.
• Many big science agencies are legally or normatively tied to peer review. For example, NIH and NSF have deep, partially statutory peer-review systems. A broad “optional” framing would push against those norms and could erode them in programs without explicit statutory protection.
• Political review of topics would formalize something the scientific community has long tried to avoid: viewpoint-based gatekeeping at the proposal level.

Who this is for

• University research offices (sponsored programs, compliance, legal counsel)
• Principal investigators and lab managers in federally funded fields
• Startups and small businesses using SBIR/STTR or cooperative agreements
• Nonprofit research institutes and consortia
• State and local labs collaborating with federal agencies

Potential impacts, with examples

• Long-horizon projects face higher risk:

  • Astronomy: A multi-year instrumentation award could be canceled mid-build, wasting sunk costs and delaying observatory schedules.
  • Climate and ecology: Seasonal field campaigns and longitudinal datasets depend on continuity; gaps reduce scientific value.
  • Clinical research: Early patient enrollment under a federal grant, followed by midstream cancellation, can strand participants and complicate ethics oversight.

• Hiring and training uncertainty:

  • Labs may hesitate to recruit PhD students or postdocs on federal dollars if termination risk spikes.
  • International talent may prefer systems with steadier funding, weakening US competitiveness.

• Startups and translational pipelines:

  • SBIR-funded companies planning milestones could face cash-flow cliffs if termination is easier to invoke.
  • Follow-on investment might dry up if federal awards no longer signal programmatic commitment.

• Chilling effects on topics:

  • Researchers may quietly pivot away from areas perceived as controversial, even if those are scientifically urgent or congressionally prioritized in appropriations.

Legal and policy guardrails to know

• Statutory requirements: Some agencies (e.g., NIH, NSF) have laws and charters that embed merit review and advisory councils. A general OMB policy cannot erase statutory mandates; conflicts would be litigated.
• Administrative Procedure Act (APA): Major rule changes must be reasoned and responsive to evidence. Arbitrary or capricious shifts can be challenged.
• Constitutional concerns: Conditions that penalize protected academic speech or impose viewpoint discrimination can trigger First Amendment scrutiny, though courts distinguish between government speech, programmatic priorities, and private speech.
• Appropriations directives: Congress often tells agencies what to prioritize. If topic bans or cancellations clash with appropriations language, that invites oversight or rescission.

Bottom line: Even if finalized, broad “cancel-anytime” and topic-screening powers would not be limitless—they’d be tested against statutes, the APA, and oversight.

Possible benefits claimed—and the trade-offs

• Claimed benefits:

  • Flexibility: Agencies can reallocate funds quickly as priorities shift.
  • Accountability: Ability to end underperforming or misaligned projects faster.
  • Speed: Bypassing lengthy peer review might accelerate certain programs.

• Trade-offs and risks:

  • Lower predictability raises costs and reduces participation, especially for high-risk, long-term science.
  • Without robust peer review, error rates rise: more weak projects funded, strong ones missed.
  • Political screening deters innovation in sensitive but vital fields and undermines public trust in federal science.

Practical steps for research teams and institutions

1. Map exposure

   • Inventory active awards by agency, duration, and critical dependencies (personnel, equipment leases, clinical obligations).
   • Flag projects where termination would create safety, ethical, or data-integrity risks.

2. Strengthen award terms

   • Negotiate clearer termination and closeout clauses where possible.
   • Seek milestone-based payments and early deliverables to reduce stranded costs.

3. Diversify funding

   • Increase applications to private foundations, philanthropy, and state programs.
   • Consider blended portfolios (grants plus fee-for-service or contracts) to spread risk.

4. Build contingency reserves

   • Encourage departments to hold small internal bridge funds for trainees and critical experiments.

5. Document merit and progress

   • Maintain rigorous records of aims, outputs, and compliance to counter any claim of nonperformance.

6. Ethics and participant protections

   • For human and animal research, pre-plan ethical wind-down procedures to avoid harm if funding stops suddenly.

7. Engage in rulemaking

   • Submit data-rich comments during the public comment window.
   • Coordinate with professional societies (AAU, APLU, AAAS, FASEB, etc.) to amplify evidence and legal analysis.

What researchers can say in public comments

• Provide concrete evidence: timelines, costs, publication lags, and training pipelines that depend on stable funding.
• Explain why peer review improves outcomes: cite acceptance/retraction rates, replication success, and comparative data from internal-only review.
• Quantify sunk costs from midstream cancellations and ethics risks in human/animal studies.
• Highlight statutory conflicts for your agency and program.

Tip: Comments that include data, real examples, and legal citations carry more weight than form letters.

International and economic context

• The US has long attracted global talent because federal grants are comparatively stable and merit-driven.
• Other nations are investing in long-term R&D missions (semiconductors, clean energy, AI). If US awards become unreliable, multinational firms and top researchers may shift labs and manufacturing to jurisdictions with steadier support.
• University-led research clusters drive regional economies; uncertainty can slow lab expansions, industry partnerships, and tech transfer.

What if these rules are finalized?

• Expect litigation: Universities, associations, and states may sue over conflicts with agency statutes and the APA.
• Look for agency-by-agency variability: Some programs will retain peer review under statutory or policy commitments; others may shift more dramatically.
• Watch appropriations riders: Congress can nudge or block implementation in specific programs.
• Prepare for transition clauses: Existing awards might be modified at renewal or supplement stages; read all amendments carefully.

Key takeaways

• The proposal centers on three levers: cancel-at-will authority, optional peer review, and political topic screening. Together, they would reduce the independence and predictability of US research funding.
• Impacts would be uneven but significant for long-duration, infrastructure-heavy, or ethically sensitive research—and for early-career scientists.
• Statutes, the APA, and congressional oversight are potential guardrails, but they are not automatic; stakeholders should participate in the comment process and prepare risk mitigations now.

FAQ

Q: Can an agency really cancel a grant if I’m meeting milestones?
A: Under a broad “termination for convenience” approach, yes—if the final rules permit it. Today, cancellations typically require cause or mutual agreement. The proposal would tilt toward agency discretion, though legal and contractual limits would still apply.

Q: Does this eliminate peer review at NIH or NSF?
A: Not outright. Those agencies have deep, partly statutory peer-review systems. But a government-wide push that treats peer review as optional can erode norms in programs without explicit protections and could affect how non-traditional or rapid programs are run.

Q: What counts as a “forbidden topic”?
A: The proposal signals political screening for disfavored areas but doesn’t define a stable list. Historically, topics like climate impacts, reproductive health, gender/identity, gun violence, and misinformation have drawn political attention. Any screening regime invites viewpoint-based exclusions and chilling effects.

Q: Will existing awards be grandfathered?
A: It depends on how final rules are written and how agencies implement them. Some changes may apply only to new awards or to modifications and renewals. Watch for agency guidance and award amendments.

Q: How soon could this take effect?
A: Not immediately. Proposed rules go through a notice-and-comment period, potential revisions, and then finalization. Deadlines vary, and litigation could delay or alter implementation.

Q: What’s the difference between grants and contracts here?
A: Contracts already allow more government control and termination provisions aligned with procurement law. The concern is importing similar cancel-at-will control into research grants, which have historically offered more stability and investigator autonomy.

Source & original reading: https://arstechnica.com/science/2026/05/the-office-of-management-and-budget-tries-again-to-cripple-us-science/